{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:06:39Z","timestamp":1771045599877,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T00:00:00Z","timestamp":1674172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Avadel Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40801-023-00351-9","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T23:59:04Z","timestamp":1674259144000},"page":"225-234","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-5020","authenticated-orcid":false,"given":"Jennifer","family":"Gudeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,20]]},"reference":[{"issue":"1","key":"351_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/s0317167100119304","volume":"6","author":"R Broughton","year":"1979","unstructured":"Broughton R, Mamelak M. The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate. Can J Neurol Sci. 1979;6(1):1\u20136. https:\/\/doi.org\/10.1017\/s0317167100119304.","journal-title":"Can J Neurol Sci"},{"key":"351_CR2","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals, Inc. Release: Xyrem\u00ae Receives FDA Approval for the Treatment of Excessive Daytime Sleepiness in Patients With Narcolepsy. 2005. https:\/\/www.biospace.com\/article\/releases\/jazz-pharmaceuticals-inc-release-xyrem-r-receives-fda-approval-for-the-treatment-of-excessive-daytime-sleepiness-in-patients-with-narcolepsy-\/. Accessed 15 Jul 2022."},{"key":"351_CR3","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals Announces FDA Approval of Xyrem\u00ae (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients. 2018. https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-fda-approval-xyremr-sodium. Accessed 15 Jul 2022."},{"key":"351_CR4","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav\u2122 (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. 2020. http:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-approval-xywavtm-calcium. Accessed 15 Oct 2020."},{"key":"351_CR5","volume-title":"XYREM (sodium oxybate oral solution, CIII). Full Prescribing Information","author":"Jazz Pharmaceuticals","year":"2022","unstructured":"Jazz Pharmaceuticals. XYREM (sodium oxybate oral solution, CIII). Full Prescribing Information. California: Jazz Pharmaceuticals; 2022."},{"key":"351_CR6","volume-title":"XYWAV (calcium, magnesium, potassium, and sodium oxybates). Full Prescribing Information","author":"Jazz Pharmaceuticals","year":"2022","unstructured":"Jazz Pharmaceuticals. XYWAV (calcium, magnesium, potassium, and sodium oxybates). Full Prescribing Information. California: Jazz Pharmaceuticals; 2022."},{"issue":"1","key":"351_CR7","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Knudsen S, Ollila HM, Pizza F, Jennum PJ, Dauvilliers Y, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3(1):16100. https:\/\/doi.org\/10.1038\/nrdp.2016.100.","journal-title":"Nat Rev Dis Primers"},{"issue":"9560","key":"351_CR8","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499\u2013511. https:\/\/doi.org\/10.1016\/S0140-6736(07)60237-2.","journal-title":"Lancet"},{"issue":"1","key":"351_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/sleep\/30.1.13","volume":"30","author":"WT Longstreth Jr","year":"2007","unstructured":"Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007;30(1):13\u201326. https:\/\/doi.org\/10.1093\/sleep\/30.1.13.","journal-title":"Sleep"},{"key":"351_CR10","unstructured":"Narcolepsy Symptoms: Automatic Behaviors. Health Union. 2020. https:\/\/narcolepsy.sleep-disorders.net\/symptoms\/automatic-behaviors. Accessed 28 Jun 2022."},{"issue":"3","key":"351_CR11","doi-asserted-by":"publisher","first-page":"zsaa206","DOI":"10.1093\/sleep\/zsaa206","volume":"44","author":"RK Bogan","year":"2021","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, Partinen M, Del Rio Villegas R, Foldvary-Schaefer N, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3):zsaa206. https:\/\/doi.org\/10.1093\/sleep\/zsaa206.","journal-title":"Sleep"},{"key":"351_CR12","doi-asserted-by":"publisher","unstructured":"Mayer G, Plazzi G, Iranzo A, Ortega-Albas J, Quinnell T, Pesch H, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep. 2018;(9). https:\/\/doi.org\/10.1093\/sleep\/zsy128.","DOI":"10.1093\/sleep\/zsy128"},{"key":"351_CR13","unstructured":"Crane S, Sloane PD, Elder NC, Cohen LW, Laughtenschlager N, Zimmerman S. Implementing Near-Miss Reporting and Improvement Tracking in Primary Care Practices: Lessons Learned. Agency for Healthcare Research and Quality, Rockville, MD. 2017. https:\/\/www.ahrq.gov\/patient-safety\/resources\/liability\/crane.html. Accessed 4 Aug 2022."},{"issue":"4","key":"351_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5664\/jcsm.27549","volume":"5","author":"YG Wang","year":"2009","unstructured":"Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion. J Clin Sleep Med. 2009;5(4):365\u201371.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"351_CR15","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5664\/JCSM.1214","volume":"7","author":"YG Wang","year":"2011","unstructured":"Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL. Sodium oxybate: updates and correction to previously published safety data. J Clin Sleep Med. 2011;7(4):415\u20136. https:\/\/doi.org\/10.5664\/JCSM.1214.","journal-title":"J Clin Sleep Med"},{"key":"351_CR16","unstructured":"Institute for Safe Medication Practices. Quarterwatch\u2122 Report (Quarters 2 and 3, 2013): Signals for Chantix, Xyrem, Gilenya, and Tecfidera. 2014. https:\/\/www.ismp.org\/resources\/quarterwatchtm-report-quarters-2-and-3-2013-signals-chantix-xyrem-gilenya-and-tecfidera. Accessed 28 Jun 2022."},{"key":"351_CR17","unstructured":"US Food and Drug Administration. Postmarketing Surveillance Programs. 2020. https:\/\/www.fda.gov\/drugs\/surveillance\/postmarketing-surveillance-programs. Accessed 28 Jun 2022."},{"issue":"1","key":"351_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1525-1497.2003.20130.x","volume":"18","author":"SR Ahmad","year":"2003","unstructured":"Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003;18(1):57\u201360. https:\/\/doi.org\/10.1046\/j.1525-1497.2003.20130.x.","journal-title":"J Gen Intern Med"},{"issue":"9","key":"351_CR19","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881\u201393. https:\/\/doi.org\/10.5664\/jcsm.9328.","journal-title":"J Clin Sleep Med"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-023-00351-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-023-00351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T12:15:31Z","timestamp":1685535331000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-023-00351-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,20]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s40801-023-00351-9","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,20]]},"assertion":[{"value":"5 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Avadel Pharmaceuticals (Chesterfield, MO) funded editorial support provided by The Curry Rockefeller Group, LLC (Tarrytown, NY) and the open access fee for this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors are employees of Avadel Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests\/competing interest"}},{"value":"The datasets analyzed during the current study are available in the FDA Adverse Event Reporting System (FAERS) database, available at: <u>,<\/u> and will be shared on reasonable request to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This research study was conducted retrospectively from publicly available data and ethics approval was not needed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish\/participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"The authors confirm responsibility for the following: study conception and design, data collection, analysis and interpretation of results, and writing the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}